302 related articles for article (PubMed ID: 28972818)
1. Neuron-Specific Enolase as an Immunohistochemical Marker Is Better Than Its Reputation.
Mjønes P; Sagatun L; Nordrum IS; Waldum HL
J Histochem Cytochem; 2017 Dec; 65(12):687-703. PubMed ID: 28972818
[TBL] [Abstract][Full Text] [Related]
2. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours.
Kasprzak A; Zabel M; Biczysko W
Pol J Pathol; 2007; 58(1):23-33. PubMed ID: 17585539
[TBL] [Abstract][Full Text] [Related]
3. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
4. Secretagogin is a new neuroendocrine marker in the human prostate.
Adolf K; Wagner L; Bergh A; Stattin P; Ottosen P; Borre M; Birkenkamp-Demtröder K; Orntoft TF; Tørring N
Prostate; 2007 Apr; 67(5):472-84. PubMed ID: 17285592
[TBL] [Abstract][Full Text] [Related]
5. Secretagogin is a novel marker for neuroendocrine differentiation.
Birkenkamp-Demtröder K; Wagner L; Brandt Sørensen F; Bording Astrup L; Gartner W; Scherübl H; Heine B; Christiansen P; Ørntoft TF
Neuroendocrinology; 2005; 82(2):121-38. PubMed ID: 16449819
[TBL] [Abstract][Full Text] [Related]
6. Secretagogin, a novel neuroendocrine marker, has a distinct expression pattern from chromogranin A.
Lai M; Lü B; Xing X; Xu E; Ren G; Huang Q
Virchows Arch; 2006 Oct; 449(4):402-9. PubMed ID: 16955307
[TBL] [Abstract][Full Text] [Related]
7. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
Baudin E; Gigliotti A; Ducreux M; Ropers J; Comoy E; Sabourin JC; Bidart JM; Cailleux AF; Bonacci R; Ruffié P; Schlumberger M
Br J Cancer; 1998 Oct; 78(8):1102-7. PubMed ID: 9792158
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine marker expression in thyroid epithelial tumors.
Satoh F; Umemura S; Yasuda M; Osamura RY
Endocr Pathol; 2001; 12(3):291-9. PubMed ID: 11740050
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL
Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329
[TBL] [Abstract][Full Text] [Related]
10. The expression of keratins, vimentin, neurofilament proteins, smooth muscle actin, neuron-specific enolase, and synaptophysin in tumors of the specific glands in the canine anal region.
Vos JH; van den Ingh TS; Ramaekers FC; Molenbeek RF; de Neijs M; van Mil FN; Ivanyi D
Vet Pathol; 1993 Jul; 30(4):352-61. PubMed ID: 8212457
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine differentiation in colorectal carcinomas.
Syversen U; Halvorsen T; Mårvik R; Waldum HL
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine phenotype of non-small cell lung carcinoma: immunohistological evaluation and biochemical study.
Slodkowska J; Zych J; Szturmowicz M; Demkow U; Rowinska-Zakrzewska E; Roszkowski-Sliz K
Int J Biol Markers; 2005; 20(4):217-26. PubMed ID: 16398403
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of neuroendocrine markers in renal cell carcinoma.
Ronkainen H; Soini Y; Vaarala MH; Kauppila S; Hirvikoski P
Diagn Pathol; 2010 May; 5():28. PubMed ID: 20462442
[TBL] [Abstract][Full Text] [Related]
14. The value of neuroendocrine markers in non-small cell lung cancer: a comparative immunohistopathologic study.
Kiriakogiani-Psaropoulou P; Malamou-Mitsi V; Martinopoulou U; Legaki S; Tamvakis N; Vrettou E; Fountzilas G; Skarlos D; Kosmidis P; Pavlidis N
Lung Cancer; 1994 Dec; 11(5-6):353-64. PubMed ID: 7535640
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment Levels of Chromogranin A and Neuron-specific Enolase in Patients With Gastroenteropancreatic Neuroendocrine Neoplasia.
Kečkéš Š; Palaj J; Waczulíková I; Dyttert D; Mojtová E; Kováč G; Durdík Š
In Vivo; 2021; 35(5):2863-2868. PubMed ID: 34410979
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine differentiation in renal cell carcinoma--evaluation of chromogranin A and neuron-specific enolase.
Rasmuson T; Grankvist K; Roos G; Ljungberg B
Acta Oncol; 1999; 38(5):623-8. PubMed ID: 10427952
[TBL] [Abstract][Full Text] [Related]
17. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2008 Dec; 8():21. PubMed ID: 19115997
[TBL] [Abstract][Full Text] [Related]
18. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer.
Makretsov N; Gilks CB; Coldman AJ; Hayes M; Huntsman D
Hum Pathol; 2003 Oct; 34(10):1001-8. PubMed ID: 14608533
[TBL] [Abstract][Full Text] [Related]
19. Expression of pan-neuroendocrine proteins in 53 neuroblastic tumors. An immunohistochemical study with neuron-specific enolase, chromogranin, and synaptophysin.
Hachitanda Y; Tsuneyoshi M; Enjoji M
Arch Pathol Lab Med; 1989 Apr; 113(4):381-4. PubMed ID: 2495784
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
